DUBLIN and WESTLAKE VILLAGE, Calif., Aug. 5, 2015 /PRNewswire/ -- Allergan plc (NYSE: AGN) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that they have amended and restated their ...
NEW YORK, Oct. 16, 2012 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced today that trading of KYTHERA Biopharmaceuticals (Nasdaq:KYTH), a clinical-stage biopharmaceutical ...
Calabasas, Calif., March 10, 2014 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) and Bayer Consumer Care today announced that KYTHERA acquired all rights outside of the U.S. and Canada to ATX-101, ...
LOS ANGELES--(BUSINESS WIRE)-- KYTHERA Biopharmaceuticals, Inc. (“KYTHERA”) and Intendis, Bayer HealthCare’s dermatology business, today announced that they have entered into a licensing agreement ...
Kythera Biopharmaceuticals Inc., a Calabasas, Calif.-based developer of aesthetic medicines, has raised $40 million in Series C funding. JAFCO led the round, and was joined by BBT Capital ...
KYTHERA shares soar after reacquiring the full rights to its lead experimental drug outside the U.S. and Canada. Find out what this means for you. Although we don't believe in timing the market or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback